From atoms up, we assemble the perfect medicines
AI Proteins has identified miniprotein binders to more than 150 drug targets, with multiple in vivo proofs-of-concept. We are advancing novel programs, internally and with partners, that demonstrate the breadth of this modality.
Pipeline
Target
Drug class
Status
Discovery
Lead optimization
IND-enabling
TNFR1
Immunology & Inflammation
Receptor antagonist
Internal
Undisclosed
Undisclosed
Immunology & Inflammation
Undisclosed
Internal
Undisclosed
Undisclosed
Oncology
Targeted radiotherapy
Internal
Undisclosed
Mult. Undisclosed
Oncology
Targeted radiotherapy
Internal
Undisclosed
Multiple
Undisclosed
Undisclosed
Partnered
Undisclosed
Multiple
Undisclosed
Undisclosed
Partnered, BMS
Undisclosed
Partnerships
We tackle challenges that the conventional can’t resolve.
AI Proteins works with partners to translate our de novo miniprotein platform into novel, patentable molecules designed from first principles and engineered for stability, function, and precision beyond what’s possible with traditional nature-derived biologics.
